| Psoriasis vulgaris
Lexette vs Zoryve Foam
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Lexette vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Lexette based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Lexette, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lexette
Zoryve
At A Glance
Topical
Twice daily
Corticosteroid
Topical
Once daily
PDE4 inhibitor
Indications
- Psoriasis vulgaris
- Seborrheic dermatitis
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply a thin uniform film to affected skin twice daily for up to 2 weeks; shake can and invert before use; do not exceed 50 g per week; avoid face, groin, and axillae; not for use with occlusive dressings unless directed by physician.
Seborrheic dermatitis, Psoriasis vulgaris Apply a thin layer once daily to affected areas of body and/or scalp when not wet; rub in completely; for topical use only, not for ophthalmic, oral, or intravaginal use.
Contraindications
—
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=1%) Application site burning/stinging, application site pain, headache
Postmarketing Folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, miliaria
Most common (>=1%) - Seborrheic dermatitis nasopharyngitis, nausea, headache
Most common (>=1%) - Psoriasis vulgaris headache, diarrhea, nausea, nasopharyngitis
Pharmacology
Topical super-high potency corticosteroid; halobetasol propionate plays a role in cellular signaling, immune function, inflammation, and protein regulation, though its precise mechanism of action in plaque psoriasis is unknown.
PDE4 inhibitor; roflumilast and its active N-oxide metabolite inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP; the specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lexette
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Zoryve
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Lexette
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Lexette
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lexette.
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LexetteView full Lexette profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.